Human beings have always enjoyed the most expansive arsenal of any species, but at the same time, we haven’t had a chance to see anything more significant than our ability to grow on a consistent basis. We say this because the stated ability has already fetched the world some huge milestones, with technology appearing as a rather unique member of the group. The reason why technology’s credentials are so anomalous is purposed around its skill-set, which was unprecedented enough to realize all the possibilities for us that we couldn’t have imagined otherwise. Nevertheless, a closer look should be able to reveal how the whole runner was also very much inspired by the way we applied those skills across a real world environment. The latter component was, in fact, what gave the creation a spectrum-wide presence and made it the ultimate centerpiece of every horizon. Now, having such a powerful tool run the show did expand our experience in many different directions, but even after reaching so far ahead, this prodigious concept called technology will somehow keep on delivering the right goods. The same has grown to become a lot more evident in recent times, and assuming one new healthcare-themed development shakes out just like we envision, it will only propel that trend towards greater heights over the near future and beyond.
InsightRX, which provides cloud-based precision medicine software to optimize treatment decisions, has officially announced three new major enhancements for its precision dosing solutions, enhancements that are expected to be more mindful of the recent scientific and technological breakthroughs. Firstly, we must acknowledge the introduction of more accurate version of vancomycin PK dosing model for adult patients. InsightRX’s Nova precision dosing software platform offers multiple pharmacokinetic (PK) models for dosing of vancomycin. In case you weren’t aware, vancomycin is a drug used for treating and preventing bacterial infections. Anyway, under the new update, the company has installed in its precision dosing software platform a model called Modified Thomson which is recommended for adult vancomycin patients with a body mass index (BMI) under 40. The integration happened only after a study where we saw an analysis of more than 168,000 patient treatment courses. According to certain reports, the Modified Thomson model here showed higher accuracy and lower degrees of error in patients with a BMI < 40, when compared to three high-performing models. Moving on to our second enhancement, InsightRX has brought out a new MIPD (model-informed precision dosing) feature called InsightRX FitAssistSM which promises to deliver high-quality predictions. To understand the significance of such a feature, we need to understand that, in MIPD’s case, a measured level sometimes does not fit well with a model’s predictions. Now, researchers in the past have coined a solution that is concerned with using “MAP Bayesian with flattened priors.”, but initial simulations have showed that this setting can sometimes worsen predictions rather than improve them. So, how will InsightRX’s solve such a conundrum? Well, the answer is deeply rooted in its ability to assess a patient, PK model, and measured level(s) before determining whether the use of “MAP Bayesian with flattened priors” is likely to improve predictions. Currently applicable to the Buelga, Goti, and Thomson models in the vancomycin (adults) module, the FitAssist algorithm has, so far, displayed an encouraging 74% improvement in prediction accuracy.
Rounding up the highlights is a dedicated new model for adult vancomycin patients with Class III Obesity. Developed in collaboration with the University of Vermont (UVM) Health Network, the stated model was put to test during a data analysis of more than 28,000 treatment courses. The effort confirmed that this InsightRX-UVM model showed higher accuracy and lower degrees of error in patients with a BMI lower than 40, when compared to three other high-performing models.
“These new vancomycin models and the InsightRX FitAssist feature will make it easier for clinicians to provide vancomycin patients with highly accurate and individualized doses to ensure safety and efficacy,” said Sirj Goswami, PhD, CEO and co-founder of InsightRX. “And through our learnings in infectious disease treatment, we continue to advance the transformative potential of AI-enabled precision dosing into new therapeutic areas, including oncology, organ transplantation, hematology, and more. We are looking forward to discussing these new breakthroughs with attendees at ASHP.”
Founded in 2015, InsightRX has risen up the ranks by conceiving cloud-based applications for precision medicine and clinical analytics designed to individualize treatment at the point of care. The company’s approach in regards to achieving such an objective involves understanding every patient’s unique pharmacological profile, something it does through an ingenious mix of patient-specific data, pharmacology models, and machine learning.
